Research & Development

Introduction The landscape of neurological medicine is shifting rapidly as the U.S. Food and Drug Administration accelerates its evaluation of a potential breakthrough that could redefine how patients manage multiple sclerosis. This news centers on fenebrutinib, an investigational oral therapy that

The discovery of a germline mutation in a prostate cancer patient facilitates cascade testing for family members who may be at risk for breast, pancreatic, or ovarian cancers. This clinical reality highlights the expanding role of genetic identification as a cornerstone of modern oncology, moving

The appointment of industry veterans from Bristol Myers Squibb and Iovance Biotherapeutics highlights a major transition toward clinical-stage operations for cell therapy developers. This leadership influx comes at a pivotal moment for Link Cell Therapies as it progresses into the Phase I clinical

The relentless cycle of invasive eye injections for wet age-related macular degeneration has long remained the heaviest burden for patients who are struggling to preserve their vision. This central challenge defines the current management of retinal diseases, where the high frequency of treatments

Raw material imports for medicine currently account for $749 million in annual spending, representing more than half of the country's total medicinal foreign-exchange costs. This financial burden has catalyzed a strategic pivot toward domestic biotechnology, as the nation seeks to insulate its

The core architecture of a chimeric antigen receptor relies on a single-chain variable fragment linked to intracellular signaling components that ignite T cell proliferation. As the pharmaceutical industry entered the second half of the current decade, the shift from experimental novelty to